# SASH3

## Overview
The SASH3 gene encodes the protein SAM and SH3 domain containing 3, which is a lymphoid-specific adaptor protein involved in immune cell signaling. This protein is characterized by the presence of SAM (Sterile Alpha Motif) and SH3 (Src Homology 3) domains, which facilitate protein-protein interactions crucial for the organization of signaling complexes and signal transduction in lymphocytes (LabradorHorrillo2022Case; Qiu2023SASH3). SASH3 plays a significant role in T cell receptor (TCR) signaling, thymocyte survival, and the development and proliferation of CD4 T cells, acting as an anti-apoptotic factor necessary for cytokine production (Mehrabipour2023A; LabradorHorrillo2022Case). The protein is primarily expressed in lymphocytes and is involved in various signaling pathways, including those related to immune responses, such as natural killer cell-mediated cytotoxicity and Th17 cell differentiation (Chen2022PanCancer). SASH3's interactions with components of the NF-κB signaling pathway and its role in B-cell receptor signaling highlight its involvement in complex signaling networks within immune cells (Wotapek2024Roles). Additionally, SASH3 has clinical significance as a potential biomarker for cancer prognosis, with its expression levels being associated with survival outcomes in various cancers (Chen2022PanCancer).

## Structure
The SASH3 protein, encoded by the SASH3 gene, is characterized by the presence of SAM (Sterile Alpha Motif) and SH3 (Src Homology 3) domains, which are crucial for its function in immune cell signaling (LabradorHorrillo2022Case; Qiu2023SASH3). These domains facilitate protein-protein interactions, playing a significant role in the organization of signaling complexes and signal transduction in lymphocytes (Qiu2023SASH3). The SAM domain is typically involved in mediating protein-protein interactions, while the SH3 domain is known for binding to proline-rich motifs in other proteins, contributing to the protein's tertiary structure.

The SASH3 protein is implicated in various signaling pathways, including those related to immune responses, such as natural killer cell-mediated cytotoxicity and Th17 cell differentiation (Chen2022PanCancer). The protein's structure and function may be regulated by post-translational modifications, such as phosphorylation, although specific details on these modifications are not provided in the context.

The truncation of the SASH3 protein upstream of these domains, as seen in certain genetic variants, results in a complete absence of the protein, leading to significant immunological defects (LabradorHorrillo2022Case). This highlights the importance of the SAM and SH3 domains in maintaining the protein's functional integrity.

## Function
The SASH3 gene encodes a lymphoid-specific adaptor protein known as SH3-containing lymphocyte protein (SLY1), which plays a crucial role in T cell receptor (TCR) signaling and thymocyte survival in healthy human cells (LabradorHorrillo2022Case). SASH3 is involved in the development and proliferation of CD4 T cells and is essential for cytokine production, acting as an anti-apoptotic factor necessary for these processes (LabradorHorrillo2022Case). The protein functions as an adaptor, facilitating the assembly of signaling complexes and mediating protein interactions necessary for cellular signaling pathways (Mehrabipour2023A).

SASH3 is primarily expressed in lymphocytes and is involved in signal transduction cascades crucial for immune responses (Chen2022PanCancer). It contains protein-protein interaction domains that link receptors to downstream signaling components, which are critical for signaling and regulation (Mehrabipour2023A). In the context of immune function, SASH3 is phosphorylated at Ser27 following T-cell receptor ligation and protein kinase C activation, highlighting its role in T-cell receptor signaling (Qiu2023SASH3). The absence or deficiency of SASH3 can lead to significant immunological abnormalities, including impaired TCR signaling and thymocyte survival, which underscores its importance in maintaining normal immune cell function (LabradorHorrillo2022Case).

## Clinical Significance
The SASH3 gene has been implicated in various cancers and is considered a potential biomarker for cancer prognosis. In lung adenocarcinoma (LUAD), elevated SASH3 expression is an independent prognostic factor associated with poorer overall survival (OS), disease-specific survival (DSS), and progression-free survival (PFS) (Chen2022PanCancer). High SASH3 expression is linked to worse OS in esophageal squamous cell carcinoma (ESCC), acute myeloid leukemia (AML), low-grade glioma (LGG), and uveal melanoma (UVM), but is associated with better OS in cervical squamous cell carcinoma (CESC), head and neck squamous cell carcinoma (HNSC), LUAD, sarcoma (SARC), skin cutaneous melanoma (SKCM), thymoma (THYM), and uterine corpus endometrial carcinoma (UCEC) (Chen2022PanCancer).

In AML, SASH3 is considered an unfavorable prognostic immune biomarker, with higher expression correlating with poorer survival outcomes and increased immune cell infiltration (Qiu2023SASH3). SASH3 expression is also associated with immune-related pathways and tumor microenvironment interactions, influencing tumor progression and drug response (Chen2022PanCancer). DNA methylation of SASH3 affects its expression and prognosis in several cancers, with high methylation linked to better OS in kidney renal clear cell carcinoma (KIRC) and UVM, but poor OS in SKCM (Chen2022PanCancer).

## Interactions
SASH3, also known as SAM and SH3 domain containing 3, is involved in various protein-protein interactions, primarily within immune cell signaling pathways. It contains SH3 and SAM domains, which facilitate its role as an adaptor protein, linking receptors to downstream signaling components (Mehrabipour2023A). In B-cell Non-Hodgkin lymphoma, SASH3 interacts with proteins involved in B-cell receptor (BCR) signaling, such as SYK, BTK, and PLCγ2, despite BCR signaling not being an enriched GO class (Wotapek2024Roles). 

SASH3 also interacts with components of the NF-κB signaling pathway, which is unexpected in certain subtypes of lymphoma that are generally not dependent on this pathway (Wotapek2024Roles). In diffuse large B-cell lymphoma (DLBCL), SASH3 interacts with many NF-κB signaling factors, suggesting a potential regulatory role in PI3K signaling, which is crucial for germinal center B-cell-like (GCB) DLBCL cells (Wotapek2024Roles). 

Additionally, SASH3 has been identified to interact with proteins such as BLNK, CARD11, and members of the NF-κB signaling pathway, although these interactions appear to be indirect as their phosphorylation was not significantly altered upon SASH3 knockout (Wotapek2024Roles). These interactions highlight SASH3's involvement in complex signaling networks within immune cells.


## References


[1. (Mehrabipour2023A) Mehrnaz Mehrabipour, Neda S. Kazemein Jasemi, Radovan Dvorsky, and Mohammad R. Ahmadian. A systematic compilation of human sh3 domains: a versatile superfamily in cellular signaling. Cells, 12(16):2054, August 2023. URL: http://dx.doi.org/10.3390/cells12162054, doi:10.3390/cells12162054. This article has 9 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cells12162054)

[2. (LabradorHorrillo2022Case) Moisés Labrador-Horrillo, Clara Franco-Jarava, Marina Garcia-Prat, Alba Parra-Martínez, María Antolín, Sandra Salgado-Perandrés, Aina Aguiló-Cucurull, Mónica Martinez-Gallo, and Roger Colobran. Case report: x-linked sash3 deficiency presenting as a common variable immunodeficiency. Frontiers in Immunology, April 2022. URL: http://dx.doi.org/10.3389/fimmu.2022.881206, doi:10.3389/fimmu.2022.881206. This article has 9 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fimmu.2022.881206)

3. (Wotapek2024Roles) Roles of MARCH5 and SASH3 in oncogenic signalling in B-cell Non-Hodgkin lymphoma. This article has 0 citations.

[4. (Chen2022PanCancer) Xi Chen, Yixiao Yuan, Wenjun Ren, Fan Zhou, Xiaobin Huang, Jun Pu, Xiaoqun Niu, and Xiulin Jiang. Pan-cancer integrated analysis identification of sash3, a potential biomarker that inhibits lung adenocarcinoma progression. Frontiers in Oncology, June 2022. URL: http://dx.doi.org/10.3389/fonc.2022.927988, doi:10.3389/fonc.2022.927988. This article has 3 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fonc.2022.927988)

5. (Qiu2023SASH3) SASH3 is an unfavorable prognostic immune biomarker in patients with acute myeloid leukemia(AML). This article has 0 citations.